Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Adjuvant chemotherapy (ACT) for breast cancer (BC) has been successfully used as part of complex treatment for several decades. The concept of BC as a systemic disease has made it possible to develop optimal treatment algorithms, including both local methods of disease control, such as surgery and radiation therapy, and systemic drug treatment. The effectiveness of adjuvant systemic therapy in increasing overall and relapse-free survival is not in doubt, however, the optimal timing of initiation of chemotherapy after radical surgical treatment has not been reliably determined to date. Many factors, such as age, comorbidity, type of surgery, and patient compliance with treatment, can delay chemotherapy. We analyzed the largest studies in this area to gain insight into what may cause delays in adjuvant treatment and the long-term consequences of such delays for the patient.

全文:

受限制的访问

作者简介

G. Dashyan

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

编辑信件的主要联系方式.
Email: dgarik@mail.ru
ORCID iD: 0000-0001-6183-9764
SPIN 代码: 6989-7148
Scopus 作者 ID: 17344871400

Dr. Sci. (Med.), Head of Oncology Department № 1 (Surgical Methods for the Treatment of Tumors of the Breast, Skin and Soft Tissues)

俄罗斯联邦, St. Petersburg

V. Konstantinova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0001-9650-7305
俄罗斯联邦, St. Petersburg

E. Dzhelialov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-2571-243X
SPIN 代码: 7261-2325
俄罗斯联邦, St. Petersburg

R. Akhmedov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0003-3348-4251
俄罗斯联邦, St. Petersburg

Yu. Semiletova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0001-5706-250X
俄罗斯联邦, St. Petersburg

A. Zhurov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0009-0004-7511-2952
俄罗斯联邦, St. Petersburg

A. Tyusenko

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0003-0689-6058
SPIN 代码: 9223-5741
俄罗斯联邦, St. Petersburg

A. Olchonova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
俄罗斯联邦, St. Petersburg

I. Pavlikova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-1753-6296
俄罗斯联邦, St. Petersburg

A. Belousov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-2274-8170
俄罗斯联邦, St. Petersburg

参考

  1. Всемирная организация здравоохранения, 2023 г. [The World Health Organization 2023. (In Russ.)].
  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi: 10.1016/S0140-6736(05)66544-0.
  3. Engel J., Eckel R., Kerr J., et al. The process of metastasisation for breast cancer. Eur J Cancer. 2003;39(12):1794–806. doi: 10.1159/000323483.
  4. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastas Rev. 1990;9(3):171–74. doi: 10.1007/BF00046358.
  5. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33.
  6. Fisher B., Gunduz N., Coyle J., et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Canc. Res. 1989;49(8):1996–2001. Heppner GH: In vitro studies on cell-mediated.
  7. Heppner G.H. In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int J Canc. 1972;9(1):119–25. doi: 10.1002/ijc.2910090114.
  8. Fisher B., Gunduz N., Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Canc Res. 1983;43(4):1488–92.
  9. Kupstas A.R., Hoskin T.L., Day C.N., et al. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a national cancer database analysis. Ann Surg Oncol. 2019;26(10):3240–9. doi: 10.1245/s10434-019-07566-7.
  10. Downing A., Twelves C., Forman D., et al. Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 2014;20(1):29–36. doi: 10.1111/tbj.12209.
  11. Chavez-MacGregor M., Clarke C.A., Lichtensz-tajn D.Y., et al. Delayed initiation of adjuvant chemotherapy among patients with breast Cancer. JAMA. Oncol. 2016;2(3):322–29. doi: 10.1001/jamaoncol.2015.3856.
  12. Nurgalieva Z.Z., Franzini L., Morgan R.O., et al. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30(1):419. doi: 10.1007/s12032-012-0419-1.
  13. Farolfi A., Scarpi E., Rocca A., et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer. 2015;51(14):1874–81. doi: 10.1016/j.ejca.2015.07.003.
  14. Shannon C., Ashley S., Smith I.E. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J ClinOncol. 2003;21(20):3792–97. doi: 10.1200/JCO.2003.01.073.
  15. Jara Sanchez C., Ruiz A., Martin M., et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM)[J]. Breast Cancer Res Treat. 2007;101(2):215–23. doi: 10.1007/s10549-006-9282-0.
  16. Cold S., During M., Ewertz M., et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)[J]. Br J Cancer. 2005;93(6):627–32. doi: 10.1038/sj.bjc.6602734.
  17. Yu K.D., Huang S., Zhang J.X., et al. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC. Cancer. 2013;13:240. doi: 10.1186/1471-2407-13-240.
  18. Raphael M.J., Biagi J.J., Kong W., et al. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016; 160(1):17–28. doi: 10.1007/s10549-016- 3960-3.
  19. Biagi J.J., Raphael M.J., King W.D., et al. The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. JAMA. 2011;29(15):1128. doi: 10.1200/jco.2011.29.15_suppl.1128.
  20. Lohrisch C., Paltiel C., Gelmon K., et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-s tage breast cancer. J Clin Oncol. 2006;24(30):4888–94. doi: 10.1200/JCO.2005.01.6089.
  21. Gagliato D.M., Gonzalez-Angulo A.M., Lei X., et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32(8):735–44. doi: 10.1200/JCO.2013.49.7693.
  22. Morante Z., Ruiz R., Araujo J.M., et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast Cancer. Clin Breast Cancer. 2021;21(3):239–46 e234. doi: 10.1016/j.clbc.2020.09.008.
  23. Ashok Kumar P., Paulraj S., Wang D., et al. Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol. 2021; 147(8):2447–58. doi: 10.1007/s00432-021- 03525-6.
  24. He X., Ye F., Zhao B., et al. Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: a systematic review and meta-analysis involving 186982 patients. PLoS One. 2017;12(3):e0173862. doi: 10.1371/journal.pone.0173862.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##